ProMIS Ebit Per Revenue from 2010 to 2024

PMN Stock  USD 0.94  0.02  2.17%   
ProMIS Neurosciences Ebit Per Revenue yearly trend continues to be very stable with very little volatility. Ebit Per Revenue is likely to drop to -1,224. During the period from 2010 to 2024, ProMIS Neurosciences Ebit Per Revenue quarterly data regression pattern had range of 21.4 K and standard deviation of  5,476. View All Fundamentals
 
Ebit Per Revenue  
First Reported
2010-12-31
Previous Quarter
-1.2 K
Current Value
-1.2 K
Quarterly Volatility
5.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ProMIS Neurosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProMIS Neurosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 46.1 K, Interest Expense of 191.3 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 5.1 K, Dividend Yield of 0.0 or PTB Ratio of 2.7. ProMIS financial statements analysis is a perfect complement when working with ProMIS Neurosciences Valuation or Volatility modules.
  
Check out the analysis of ProMIS Neurosciences Correlation against competitors.
To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.

Latest ProMIS Neurosciences' Ebit Per Revenue Growth Pattern

Below is the plot of the Ebit Per Revenue of ProMIS Neurosciences over the last few years. It is ProMIS Neurosciences' Ebit Per Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProMIS Neurosciences' overall financial position and show how it may be relating to other accounts over time.
Ebit Per Revenue10 Years Trend
Pretty Stable
   Ebit Per Revenue   
       Timeline  

ProMIS Ebit Per Revenue Regression Statistics

Arithmetic Mean(2,492)
Coefficient Of Variation(219.74)
Mean Deviation3,100
Median(1,014)
Standard Deviation5,476
Sample Variance30M
Range21.4K
R-Value(0.19)
Mean Square Error31.1M
R-Squared0.04
Significance0.50
Slope(233.09)
Total Sum of Squares419.8M

ProMIS Ebit Per Revenue History

2024 -1223.97
2023 -1165.68
2021 -1013.64
2020 -3168.66
2019 -6153.29
2018-21.4 K
2017 -607.67

About ProMIS Neurosciences Financial Statements

ProMIS Neurosciences investors utilize fundamental indicators, such as Ebit Per Revenue, to predict how ProMIS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Ebit Per Revenue-1.2 K-1.2 K

Pair Trading with ProMIS Neurosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProMIS Neurosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProMIS Neurosciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with ProMIS Stock

  0.64ELAN Elanco Animal HealthPairCorr

Moving against ProMIS Stock

  0.83EWTX Edgewise TherapeuticsPairCorr
  0.81ESPR Esperion Therapeutics Buyout TrendPairCorr
  0.77BMY Bristol Myers Squibb Sell-off TrendPairCorr
  0.77GILD Gilead SciencesPairCorr
  0.68EBS Emergent BiosolutionsPairCorr
The ability to find closely correlated positions to ProMIS Neurosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProMIS Neurosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProMIS Neurosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProMIS Neurosciences to buy it.
The correlation of ProMIS Neurosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProMIS Neurosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProMIS Neurosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProMIS Neurosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether ProMIS Neurosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProMIS Neurosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Promis Neurosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Promis Neurosciences Stock:
Check out the analysis of ProMIS Neurosciences Correlation against competitors.
To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.04
Revenue Per Share
0.001
Return On Assets
(4.81)
Return On Equity
(10.99)
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.